. 2018 Jun;24(6):10.18553/jmcp.2018.24.6.525. doi: 10.18553/jmcp.2018.24.6.525

TABLE 3.

After Propensity Score Matching: Comparison of Health Care Costs by First Targeted Therapy Among Cohorts During TOT

Monthly per Patient Costs to Payer (2015 USD)	Pazopanib, n = 522		Sunitinib, n = 522		Mean Difference [A] - [B]	P Value
Monthly per Patient Costs to Payer (2015 USD)	Mean [A] ± SD	Median [A]	Mean [B] ± SD	Median [B]	Mean Difference [A] - [B]	P Value
All-cause
Total all-cause health care costs	8,527 ± 6,264	7,013	10,924 ± 9,365	8,357	-2,397	< 0.001^a
Total all-cause medical costs	3,991 ± 5,971	1,562	5,881 ± 9,057	2,499	-1,890	< 0.001^a
Inpatient costs	2,040 ± 5,084	0	3,731 ± 8,316	0	-1,692	< 0.001^a
Emergency room costs	73 ± 239	0	115 ± 315	0	-42	0.005^a
Outpatient costs	477 ± 722	272	385 ± 509	219	92	0.116
Skilled nursing facility costs	156 ± 832	0	369 ± 1,500	0	-213	0.002^a
Home health agency costs	230 ± 590	0	303 ± 662	0	-74	0.028^a
Other medical service costs	1,016 ± 2,160	382	977 ± 1,370	425	39	0.226
Total all-cause pharmacy costs	4,536 ± 2,171	4,510	5,043 ± 2,413	4,838	-506	< 0.001^a
RCC diagnosis-associated
Inpatient costs	1,166 ± 3,509	0	2,495 ± 7,116	0	-1,329	< 0.001^a
Emergency room costs	27 ± 137	0	46 ± 197	0	-19	0.047^a
Outpatient costs	309 ± 506	153	232 ± 415	108	77	0.002^a

Note: Costs were measured from treatment initiation to the earliest of treatment discontinuation or death (TOT perspective).

^aP < 0.05 for pairwise comparison of the pazopanib cohort with the sunitinib cohort using Wilcoxon signed-rank tests.

RCC= renal cell carcinoma; SD = standard deviation; TOT = time on treatment; USD = U.S. dollars.